Login to Your Account



Concert Sings 'All That Jazz' with D-SXB Licensing Deal

By Marie Powers
Staff Writer

Wednesday, March 6, 2013
Privately held Concert Pharmaceuticals Inc. struck another business development high note, inking an exclusive license agreement that provides Jazz Pharmaceuticals plc with global rights to develop and commercialize deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323, aimed at narcolepsy.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription